Alto Neuroscience

#ICYMI, last week Alto Neuroscience scientists were pleased to present new data at the 64th Annual Meeting of the American College of Neuropsychopharmacology. This meeting is one of the most highly regarded conferences in psychiatry and served as an exciting start to 2026 to showcase the breadth and depth of our precision platform. Read more here: https://lnkd.in/gFK55dXp   #ACNP26 #PrecisionPsychiatry #DepressionResearch

#ICYMI, our CEO, Amit Etkin, sat down with Jonah Comstock, Editor-in-Chief of Pharmaphorum, during #JPM26 to discuss what’s ahead for Alto Neuroscience—from upcoming clinical readouts in schizophrenia, depression, and bipolar disorder to our biology-driven approach for patients with limited options today. 🎥 Watch the full interview here: https://lnkd.in/ga5u2Vjj #JPMWeek #PrecisionPsychiatry #Neuroscience #MentalHealth #HealthcareInnovation

Alto Neuroscience announced the issuance of a new U.S. method-of-treatment patent for ALTO-207 in depression – further strengthening the foundation behind this differentiated program for patients with treatment-resistant depression. With issued and pending claims, the ALTO-207 intellectual property portfolio is expected to extend into the mid-2040s, reinforcing long-term value as the program advances. Read more here: https://lnkd.in/gkKv7ijx #Biotech #PrecisionPsychiatry #DepressionResearch #Neuroscience

Tune in next week to hear about the exciting work going on at Alto Neuroscience to advance #precisionpsychiatry!

Today, Alto Neuroscience reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. Learn more here: https://lnkd.in/gs3aW3nf

A proud day for Alto Neuroscience at the NYSE. We rang the Opening Bell today to celebrate our ongoing commitment to transforming the treatment of mental health disorders through precision psychiatry. As we look ahead, we remain focused on our core mission - leveraging individuals' neurobiology to develop novel neuropsychiatric medicines that help patients get better faster.

We’re looking forward to connecting with investors and pharma at the upcoming Stifel 2025 Healthcare Conference and the Jefferies London Healthcare Conference. Alto Neuroscience’s leadership team will participate in fireside chats and one-on-one meetings to discuss our progress advancing precision psychiatry. ·       Stifel Healthcare Conference — November 12, 10:00–10:30 AM ET, New York, NY ·       Jefferies London Healthcare Conference — November 17, 3:30–3:55 PM GMT, London, UK Webcasts will be available on the Investors – Events & Presentations page of our website following each session. Read more here: https://lnkd.in/gjzApQAk #AltoNeuroscience #PrecisionPsychiatry 

Alto Neuroscience is pleased to announce the close of a $50 million private placement financing, led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital LP, Vestal Point Capital, and a large biotech-dedicated investor. Alto intends to use the proceeds to accelerate the development of ALTO-207, a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist) and ondansetron, following a successful FDA meeting regarding the development path of the program, as well as for working capital and general corporate purposes.  Read more here: https://lnkd.in/gBhKAp_H   #TRD #financing #biotech #neuroscience #precisionpsychiatry

Alto Neuroscience announced today that it will accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD), following a successful outcome from a recent meeting with the FDA.   The $50 million private placement announced earlier today supports expanded development of ALTO-207, and the Company expects to initiate a Phase 3 study by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned study design.   Read more here: https://lnkd.in/gYJGjEZR #TRD #biotech #neuroscience

We’re excited to share that Dr. Mike Browning presented data from the results from the PAX-D study, as previously published in The Lancet, at the #ECNP Congress 2025 today. The PAX-D results guided Alto Neuroscience’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole. This presentation highlights the potential of ALTO-207, which we believe represents an important step forward in bringing precision psychiatry to those living with depression. #ECNP2025 #AltoNeuroscience #PrecisionPsychiatry #MentalHealthInnovation